An Open-Label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-Line Treatment of Subjects With Predominantly Non-Squamous Cell Stage IIIBwet/IV Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2015
At a glance
- Drugs Pazopanib (Primary) ; Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline
- 08 Oct 2015 Status changed from completed to discontinued according to results published in the Journal of Thoracic Oncology.
- 07 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 07 Apr 2011 Status changed from active, no longer recruiting to completed. as reported by ClinicalTrials.gov.